Clinical Trial Update: Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describes a Phase 1/2 study of oral decitabine/cedazuridine (DEC-C) in combination with nivolumab for patients with mucosal melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Mucosal Melanoma

Drugs mentioned

• DEC-C (oral decitabine/cedazuridine) (decitabine; cedazuridine)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING